Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts
Mayo Clinic
Summary
This study evaluates individuals without pancreatic cancer, but who have been determined to be at higher-than-average lifetime risk of developing pancreatic cancer to help detect pancreatic cancer or other cancers at an earlier time when they might be more easily treated and cured.
Description
PRIMARY OBJECTIVES: I. To develop a cohort (biobank of biospecimens and data) of subjects without pancreatic cancer who are at highrisk for pancreatic cancer due to: a strong family history, a mutation in a known pancreatic cancer predisposition gene, or fukuoka worrisome or high-risk pancreatic cysts. II. To follow the cohort subjects longitudinally and collect biospecimens and follow-up data and record medical outcomes. III. To make biospecimen available to PCDC-approved projects to validate potential biomarkers for performance using nested case-control prospective designs. OUTLINE: This…
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * PDAC FAMILY HISTORY OR PDAC RELATED GENETIC MUTATIONS: * Age: 50 or older, plus at least one of the following: * Mutation unknown or absent: * 2+ relatives with PDAC on same side of family where 2 affected are first degree related to each other and at least 1 affected is first degree related to subject; * OR 2+ affected first degree relatives \[(FDR), defined as blood related parents, siblings, or children\] * Known pathogenic/likely pathogenic (P/LP) mutation in at least one of the following: * CDKN2A/p16, Peutz-Jeghers syndrome (PJS) ser…
Interventions
- OtherNon-Interventional Study
Non-interventional study
Locations (7)
- HonorHealth Research InstituteScottsdale, Arizona
- Piedmont HealthcareAtlanta, Georgia
- OSF Saint Francis Medical CenterPeoria, Illinois
- Mayo Clinic in RochesterRochester, Minnesota
- University of Nebraska Medical CenterOmaha, Nebraska
- Oregon Health & Science UniversityPortland, Oregon